Detection of <i>BRCA1</i>, and <i>BRCA2</i> Alterations in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World Setting

Background: Poly (ADP-ribose) polymerase (PARP) inhibitors are approved for patients with metastatic castration-resistant prostate cancer harboring deleterious or suspected deleterious <i>BRCA1</i> and/or <i>2</i> mutations. Identifying patients with prostate cancer harboring...

Full description

Bibliographic Details

Published in:	Biomedicines
Main Authors:	Taylor Ryan McFarland, Vinay Mathew Thomas, Roberto Nussenzveig, Georges Gebrael, Nicolas Sayegh, Nishita Tripathi, Kamal Kant Sahu, Divyam Goel, Benjamin L. Maughan, Deepika Sirohi, Neeraj Agarwal, Umang Swami
Format:	Article
Language:	English
Published:	MDPI AG 2022-12-01
Subjects:	metastatic prostate cancer BRCA PARP inhibitor cancer evolution cfDNA next-generation sequencing
Online Access:	https://www.mdpi.com/2227-9059/10/12/3170